Literature DB >> 25118615

Current developments in pharmacogenomics of multiple sclerosis.

Rebecca J Carlson1, J Ronald Doucette, Adil J Nazarali.   

Abstract

Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.

Entities:  

Mesh：

Year:  2014        PMID： 25118615     DOI： 10.1007/s10571-014-0095-0

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN： 0272-4340            Impact factor:   5.046


  15 in total

1.  HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis.

Authors:  Suhayl Dhib-Jalbut; Reuben M Valenzuela; Kouichi Ito; Michael Kaufman; Mary Ann Picone; Steve Buyske
Journal:  Mult Scler Relat Disord       Date:  2013-03-13       Impact factor: 4.339

2.  Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.

Authors:  Ekaterina Y Tsareva; Olga G Kulakova; Alexey N Boyko; Sergey G Shchur; Dmitrijs Lvovs; Alexander V Favorov; Evgeny I Gusev; Koen Vandenbroeck; Olga O Favorova
Journal:  Pharmacogenomics       Date:  2011-11-23       Impact factor: 2.533

3.  HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.

Authors:  C Fusco; V Andreone; G Coppola; V Luongo; F Guerini; E Pace; C Florio; G Pirozzi; R Lanzillo; P Ferrante; P Vivo; M Mini; M Macrì; G Orefice; M L Lombardi
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

4.  Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection.

Authors:  K Vandenbroeck; I Alloza; B Swaminathan; A Antigüedad; D Otaegui; J Olascoaga; M G Barcina; V de las Heras; M Bartolomé; M Fernández-Arquero; R Arroyo; R Alvarez-Lafuente; M C Cénit; E Urcelay
Journal:  Genes Immun       Date:  2010-09-23       Impact factor: 2.676

5.  Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.

Authors:  Robert Gross; Brian C Healy; Sabine Cepok; Tanuja Chitnis; Samia J Khoury; Bernard Hemmer; Howard L Weiner; David A Hafler; Philip L De Jager
Journal:  J Neuroimmunol       Date:  2010-11-27       Impact factor: 3.478

6.  ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

Authors:  S Cotte; N von Ahsen; N Kruse; B Huber; A Winkelmann; U K Zettl; M Starck; N König; N Tellez; J Dörr; F Paul; F Zipp; F Lühder; H Koepsell; H Pannek; X Montalban; R Gold; A Chan
Journal:  Brain       Date:  2009-07-15       Impact factor: 13.501

7.  Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Authors:  Esther Byun; Stacy J Caillier; Xavier Montalban; Pablo Villoslada; Oscar Fernández; David Brassat; Manuel Comabella; Joanne Wang; Lisa F Barcellos; Sergio E Baranzini; Jorge R Oksenberg
Journal:  Arch Neurol       Date:  2008-01-14

8.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.

Authors:  Sergio E Baranzini; Joanne Wang; Rachel A Gibson; Nicholas Galwey; Yvonne Naegelin; Frederik Barkhof; Ernst-Wilhelm Radue; Raija L P Lindberg; Bernard M G Uitdehaag; Michael R Johnson; Aspasia Angelakopoulou; Leslie Hall; Jill C Richardson; Rab K Prinjha; Achim Gass; Jeroen J G Geurts; Jolijn Kragt; Madeleine Sombekke; Hugo Vrenken; Pamela Qualley; Robin R Lincoln; Refujia Gomez; Stacy J Caillier; Michaela F George; Hourieh Mousavi; Rosa Guerrero; Darin T Okuda; Bruce A C Cree; Ari J Green; Emmanuelle Waubant; Douglas S Goodin; Daniel Pelletier; Paul M Matthews; Stephen L Hauser; Ludwig Kappos; Chris H Polman; Jorge R Oksenberg
Journal:  Hum Mol Genet       Date:  2008-11-14       Impact factor: 6.150

9.  Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

Authors:  Iris Grossman; Nili Avidan; Clara Singer; Dan Goldstaub; Liat Hayardeny; Eli Eyal; Edna Ben-Asher; Tamar Paperna; Itsik Pe'er; Doron Lancet; Jacques S Beckmann; Ariel Miller
Journal:  Pharmacogenet Genomics       Date:  2007-08       Impact factor: 2.089

10.  Glypican 5 is an interferon-beta response gene: a replication study.

Authors:  M D C Cénit; F Blanco-Kelly; V de las Heras; M Bartolomé; E G de la Concha; E Urcelay; R Arroyo; A Martínez
Journal:  Mult Scler       Date:  2009-06-25       Impact factor: 6.312
View more
  1 in total

Review 1.  Pharmacogenomics of Multiple Sclerosis: A Systematic Review.

Authors:  Keli Hočevar; Smiljana Ristić; Borut Peterlin
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.